Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

A reagent and cancer technology, applied in chemical instruments and methods, preparations for in vivo experiments, peptides, etc., can solve problems such as immunogenicity of antibodies and antibody fragments, production cost half-life limitations, etc.

Active Publication Date: 2017-08-18
RGT UNIV OF MICHIGAN
View PDF13 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application of antibodies and antibody fragments is l

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
  • Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
  • Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] Expression of EGFR extracellular domain (ECD)

[0105] The extracellular domain (ECD) of EGFR (amino acids 1-645 in domains 1-4) was cloned into the pDual GC mammalian expression vector (Stratagene, #214503). The gene was inserted between two Eam1104I restriction sites, creating a unidirectional junction. The CMV promoter drives protein expression in mammalian cells. Myc and His tags were expressed in frame on the C-terminus of recombinant EGFR-ECD for protein characterization and purification, respectively. The thrombin recognition site between EGFR-ECD and myc-His allows the tag to be cleaved after use. Correct construction was verified by DNA sequencing. The constructs were first transiently transfected into HEK-293T cells and verified on Western blot. The constructs were then introduced into Chinese Hamster Ovary (CHO) cells grown in MEMα. Stable clones were established by geneticin selection, and those with the highest expression levels were propagated and cul...

Embodiment 2

[0109] Peptides specific for EGFR

[0110] Use by express about 10 9 A phage display library (New England Biolabs, Ph.D.-12) consisting of M13 bacteriophages of unique 12-amino acid sequence was used, and peptide selection was performed according to the manufacturer's instructions. Phage library (composed of 2 × 10 9 2×10 unique clones 11 pfu, with about 100 copies per unique clone) for biopanning. Unlike the unbiased protocol performed in Li et al., Gastroenterology, 139:1472-80 (2010), biopanning was performed with a known protein target (EGFR-ECD). Four rounds of biopanning were performed using decreasing amounts (100, 80, 60 and 40 μg) of EGFR-ECD in successive rounds to increase binding specificity. After four rounds of biopanning, 50 phage colonies were randomly selected for DNA preparation and sequencing analysis. These sequences were analyzed with an ABI automatic DNA analyzer (Applied Biosystems) using a primer 5'-CCCTCATAG TTA GCG TAA CG-3' (-96gIII sequencing p...

Embodiment 3

[0116] siRNA knockdown of EGFR

[0117]We knocked down EGFR expression in HT29 cells using siRNA. We used ON-TARGETplus human EGFR siRNA and ON-TARGETplus non-targeting library (Thermo Scientific) following the manufacturer's protocol. 5 μL of siRNA (at a concentration of 5 μM / L) was transfected into HT29 cells using DharmaFECT (Thermo Scientific). QRH*-Cy5.5 and PEH*-Cy5.5 were incubated with HT29siEGFR and siCL cells. Cells were fixed with 4% PFA or methanol. A 1:1000 dilution of the primary monoclonal mouse anti-EGFR antibody (Thermo Scientific, #MS-396, clone 199.12, IgG2a isotype) was incubated overnight at 4°C. Thereafter, cells were washed 3 times with PBS and further incubated with a 1:500 dilution of AF488-labeled secondary goat anti-mouse IgG antibody (Life Technologies, #A-11029) for 1 hour at room temperature, washed 3 times and then fixed on slides with ProLong Gold reagent containing DAPI (Invitrogen). Confocal fluorescence images were collected with FITC, C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).

Description

[0001] Statement of Government Interest [0002] This invention was made with government support under U54 CA163059, R01 CA142750, U54 CA13642, U01CA189291, RO1 CA200007, and R01 EB020644 awarded by the National Institutes of Health. The government has certain rights in this invention. [0003] Incorporation by reference of material presented in electronic format [0004] Incorporated by reference in its entirety The computer-readable nucleotide / amino acid sequence listing filed with this document and identified as follows: 5,150 byte ACII (text) file named "48509_SeqListing.txt" created on August 21, 2015 . technical field [0005] The present invention relates to EGFR-specific peptide reagents, methods for detecting precancers, early cancers, and cancers using the peptide reagents, and methods for targeting precancerous cells, early cancer cells, and cancer cells using the peptide reagents. Background technique [0006] Colorectal cancer (CRC) is one of the most comm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/00
CPCA61K38/00C07K7/06C07K7/08C07K14/485G01N33/57419G01N2800/52A61K49/0056A61K49/0032A61K45/06A61K49/0043
Inventor 王敦硕周娟B.P.乔西
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap